` Comparison: 005250 vs VRTX - Alpha Spread

005250
vs
VRTX

Over the past 12 months, Green Cross Holdings has outperformed VRTX, delivering a return of -2% compared to the VRTX's 11% drop.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
005250
VRTX
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

Green Cross Holdings Intrinsic Value
HIDDEN
Show
VRTX Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Green Cross Holdings
KRX:005250
13 530 KRW
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
451.235 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
005250, VRTX

005250
VRTX
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Green Cross Holdings
Revenue
Vertex Pharmaceuticals Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
005250, VRTX

005250
VRTX
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Green Cross Holdings
KRX:005250
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Green Cross Holdings
27.5%
VRTX
86.2%

Operating Margin

Green Cross Holdings
0.8%
VRTX
39%

Net Margin

Green Cross Holdings
5.4%
VRTX
32.9%

FCF Margin

Green Cross Holdings
-4.8%
VRTX
26.6%

ROE

Green Cross Holdings
13.4%
VRTX
22.5%

ROA

Green Cross Holdings
3.2%
VRTX
16.4%

ROIC

Green Cross Holdings
0.4%
VRTX
26.9%

ROCE

Green Cross Holdings
0.7%
VRTX
23%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
005250, VRTX

Loading
005250
VRTX
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
005250, VRTX

Performance Gap Between 005250 and VRTX
HIDDEN
Show

Performance By Year
005250, VRTX

Loading
005250
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 005250 to other stocks
PNEXF
Pharnext SCA
More expensive
vs Green Cross Holdings
ABBV
Abbvie Inc
More expensive
vs Green Cross Holdings
AMGN
Amgen Inc
More expensive
vs Green Cross Holdings
GILD
Gilead Sciences Inc
More expensive
vs Green Cross Holdings
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett